July 5, 2022 —annalise.ai这家在亚太、欧洲和英国迅速发展的全球放射AI公司，今天宣布任命成功的医疗技术高管Lakshmi Gudapakkam为首席执行官，临床策略师Rick Abramson博士为首席医疗官。有了新的任命，安娜丽丝。ai expects to further accelerate its global market presence and entry into the US market following recentFDAapprovals for part of its comprehensive radiology AI product.
安娜丽丝的使命是每天帮助一百万病人。ai将尖端ai与临床专业知识相结合，将全面的ai产品迅速推向市场，具有最先进的性能，并专注于临床成功。Formed in 2019 as a joint venture between healthcare AI platformharrison.aiandI-MED Radiology Network, Australia’s largest diagnostic imaging network, the company is focused on rapidly developing and commercializing comprehensive AI products to advance patient care.
annalise.ai products have been used to help more than one million patients since launch. Annalise Enterprise CXR, the world’s first comprehensive decision-support AI solution for chest X-rays, is already in clinical use at over 400 sites in Australia and the UK and accessible by one in four Australian radiologists. A recent peer-reviewed diagnostic accuracy study published inThe Lancet Digital Healthfound Annalise Enterprise CXR improved radiologists’ diagnostic accuracy across 102 chest X-ray (CXR) findings*.
The company has clearance for clinical use for Annalise Enterprise CXR in Australia, the United Kingdom, Europe, South-East Asia, and New Zealand, and is expanding its products to new geographies. Earlier this year, Annalise Enterprise CXR receivedCADt FDA clearancefor use in triage and notification of pneumothorax and tension pneumothorax on chest X-rays.
The appointment of Lakshmi Gudapakkam as CEO will help accelerate expansion plans globally and into the US along with the development of new AI radiology tools. Mr Gudapakkam brings a wealth of healthtech expertise, serving in senior global technology andbusiness leadershiproles for more than 20 years in GE Healthcare & Philips Healthcare and for the last four years withQuest Diagnostics, as their Vice President and General Manager for their East Region.
During his time with GE Healthcare, Mr Gudapakkam led large global teams across US, Canada, Europe, India, China and Australia in large, breakthrough product development forradiology imaging, cardiology imaging and healthcare informatics.
AtPhilips Healthcare他曾负责CT和高级可视化成像领域的突破性产品。后来，古达帕卡姆进入全球商业领导岗位，在中国、印度和亚洲其他地区建立了飞利浦医疗的业务。Gudapakkam先生领导了大型全球业务，包括全球价值部门业务、全球x射线和乳房x光造影业务，以及后来的全球业务组合，包括CT、分子成像、x射线和乳房x光造影。
During his time at Quest Diagnostics, Mr Gudapakkam oversaw expansion of the company’s diagnostic services through lab management partnerships, managing the scaling of the testing through the COVID pandemic period while leading majortransformational programs including standardising IT systems and building out a mega lab in Clifton, New Jersey and consolidating lab testing in the East region.
在他的职业生涯中，Gudapakkam先生与放射学和成像的技术专家和临床专家密切合作，提供了一个广泛的网络和技能和商业头脑的完美结合，以帮助将复杂的技术转化为专业医疗保健。
Strengthening its global leadership bench even further, Rick Abramson, MD, MHCDS, FACR, joins the annalise.ai team as CMO and will be responsible for guiding the company’s clinical roadmap for international expansion. A US-based physician leader and board-certified radiologist, Dr Abramson brings more than 25 years of experience in healthcare including prior roles in clinical practice, academic research, policy development, and management. Previously corporate vice-president over the radiology service line at HCA Healthcare, Inc., Dr Abramson led enterprise strategic development for radiology and artificial intelligence across HCA’s network of 185 hospitals in the US and the UK.
In his new role with annalise.ai, Dr Abramson will help advance stakeholder partnerships with healthcare providers, technology developers and regulatory bodies across the world.
Both Mr Gudapakkam and Dr Abramson will be based in the United States, supported by a strong global team of several hundred annalise.ai staff across Australia, the UK, Europe and now US with expected growth in other locations aligned with projected business growth.
Having played an integral role in the formation and success of the joint venture, annalise.ai Founding CEODimitry Tranwill continue to serve as Director of the Board and part of the harrison.ai team.Dr Aengus Tran, Co-Founder and CEO of harrison.ai, will also continue as annalise.ai’s Chief AI Officer.
Dimitry Tran, Founding CEO and Board Director of annalise.ai, said: “We set out nearly three years ago to create a cutting-edge AI solution that empowers clinicians to make faster, more accurate decisions on radiology diagnosis. With the hard work of our global team, we’ve built an extremely strong and sustainable business with a proven model and global roadmap. To truly achieve our goals, and grow globally, we must move into the next phase of our maturity and strategy. I’m excited to welcome Mr Gudapakkam and Dr Abramson to the annalise.ai team to lead the company through this next phase of expansion and to help deliver on our mission to help one million people every day.”
克莱尔·巴特利诺，安娜丽丝的主席。他说:“拉克希米是一位杰出的高管，我们很高兴能有他来帮助推动安娜丽丝。艾未未的愿景和战略是我们公司成长的下一个阶段。他的创新方法、在健康科技领域的深厚专业知识和成熟的网络将有助于annalise的快速发展。Ai走向未来。德米特里对安娜丽丝的贡献。艾未未不知疲倦地引领了安娜丽丝的形成和发展。从艾开始。我们很高兴他将继续在安娜丽丝的未来发挥关键作用。我是董事会的董事。”
Dr Aengus Tran, Co-Founder and CEO of harrison.ai, said: “Leveraging harrison.ai’s AI capability and its leading clinical partners I-MED, annalise.ai has gone from strength to strength in taking its breakthrough radiology AI products to market. Having achieved sustainable momentum, annalise.ai is on track to help create a more equitable healthcare system for everyone. Lakshmi is well-positioned to help us achieve those goals and will ensure we have the right skills and global connections to expand our reach into new countries, new regulatory areas and new radiology products.”
Lakshmi Gudapakkam, Chief Executive Officer of annalise.ai, said: “To meet the growing demands on our global healthcare system, we need smart tools that help specialists diagnose and treat patients more effectively and accurately. The team at annalise.ai have shown an astounding ability to not only provide this capability quickly, but do so with clinical experts and patients at the forefront. I’m excited to join the team and contribute to achieving our goal of helping one million patients every day.”
*Study quote: Assisted radiologist performance — The deep-learning model statistically significantly improved the classification accuracy of radiologists for 102 (80%) of 127 clinical findings, was statistically non-inferior for 19 (15%) findings, and no findings showed a decrease in accuracy when radiologists used the deep-learning model. Unassisted radiologists had a macroaveraged mean AUC of 0·713 (0·645–0·785) across all findings, compared with 0·957 (0·954–0·959) for the model alone.
For more information:https://annalise.ai/
August 01, 2022
